BiotechTube
Xcovery

Xcovery

West Palm Beach, United States· Est.
xcovery.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

Xcovery is a private, clinical-stage biotech founded in 2006 and headquartered in West Palm Beach, Florida. The company has built a pipeline of small molecule oncology drugs, led by ensartinib, an FDA-approved ALK inhibitor for non-small cell lung cancer (NSCLC), and vorolanib, a next-generation multi-kinase angiogenesis inhibitor in development. Xcovery operates with a lean model, seeking commercial partners for ensartinib and development partners for vorolanib combinations, while leveraging the expertise of a board with deep industry and development experience.

Oncology

Technology Platform

Design and development of next-generation small molecule kinase inhibitors with a focus on improved selectivity, potency, and tolerability profiles.

Funding History

2
Total raised:$40M
Series B$25M
Series A$15M

Opportunities

Ensartinib's FDA approval provides a near-term revenue opportunity in the ALK+ NSCLC market, contingent on a strong commercial partnership.
Vorolanib represents a long-term, high-potential opportunity as a combination therapy to enhance the efficacy of immuno-oncology agents across multiple solid tumor types, tapping into the large and growing IO market.

Risk Factors

Ensartinib faces intense competition in the crowded ALK inhibitor market, creating significant commercialization risk.
Vorolanib's success is uncertain and depends on demonstrating clear clinical benefit in combination trials, a high bar in competitive IO development.
The company's reliance on securing partners for both programs introduces execution and timing risk.

Competitive Landscape

Ensartinib competes in the mature ALK+ NSCLC market against multiple approved TKIs like alectinib, brigatinib, lorlatinib, and earlier agents. Vorolanib, as an anti-angiogenic/IO combination candidate, competes in a crowded field with other TKIs and novel mechanisms being tested to overcome IO resistance, requiring clear differentiation in efficacy and safety.

More companies in Small Molecule Drugs →More companies in United States →